Hallucinogen-related emergency department visits in California rose 54% from 2016 to 2022 (2260 to 3476 visits), while alcohol-related visits fell 20% and cannabis-related visits rose 15%. Hallucinogen-related hospitalizations increased 55% (2556 to 3965), compared with a 1% increase for both alcohol and cannabis. These trends were statistically different from those for alcohol and cannabis. The absolute numbers remain small, but the relative increase is large.
A new treatment combining ketamine infusions with acceptance and commitment therapy (ACT) may be feasible for people who have both alcohol use disorder and treatment-resistant depression. In an open-label trial at a Montreal hospital, 30 participants will receive six ketamine infusions plus eight weekly therapy sessions, either in person or online. The study primarily tests whether the combined approach is practical and acceptable by measuring completion rates, safety, and data quality. Exploratory measures will track changes in depressive symptoms, alcohol use, and quality of life. Some participants will also be interviewed about their experiences.